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Ordering of mutations in acute myeloid leukemia with partial
tandem duplication of MLL (MLL-PTD)
Q-Y Sun1,10, L-W Ding1,10, K-T Tan1,10, W Chien1, A Mayakonda1, D-C Lin1,2, X-Y Loh1, J-F Xiao1, M Meggendorfer3, T Alpermann3,
M Garg1, S-L Lim1, V Madan1, N Hattori1, Y Nagata4, S Miyano5,6, AEJ Yeoh1, H-A Hou7, Y-Y Jiang1, S Takao1, L-Z Liu1, S-Z Tan1, M Lill2,
M Hayashi8, A Kinoshita8, HM Kantarjian9, SM Kornblau9, S Ogawa4, T Haferlach3, H Yang1 and HP Koeffler1,2
Partial tandem duplication of MLL (MLL-PTD) characterizes acute myeloid leukemia (AML) patients often with a poor prognosis. To
understand the order of occurrence of MLL-PTD in relation to other major AML mutations and to identify novel mutations that may
be present in this unique AML molecular subtype, exome and targeted sequencing was performed on 85 MLL-PTD AML samples
using HiSeq-2000. Genes involved in the cohesin complex (STAG2), a splicing factor (U2AF1) and a poorly studied gene, MGA were
recurrently mutated, whereas NPM1, one of the most frequently mutated AML gene, was not mutated in MLL-PTD patients.
Interestingly, clonality analysis suggests that IDH2/1, DNMT3A, U2AF1 and TET2 mutations are clonal and occur early, and MLL-PTD
likely arises after these initial mutations. Conversely, proliferative mutations (FLT3, RAS), typically appear later, are largely subclonal
and tend to be unstable. This study provides important insights for understanding the relative importance of different mutations
for defining a targeted therapeutic strategy for MLL-PTD AML patients.
Leukemia (2017) 31, 1–10; doi:10.1038/leu.2016.160
INTRODUCTION
Acute myeloid leukemia (AML) is a highly malignant hematopoietic
disorder affecting annually ~ 13 000 adults in the United States.1,2
It is a heterogeneous group of diseases classified by distinct
morphologies, karyotypes and molecular subtypes. A particularly
interesting AML subtype is the AML cases with partial tandem
duplication of the MLL gene (MLL-PTD), characterized by the
internal partial tandem duplication of exons 3–9 or 3–11 in the MLL
gene. MLL-PTD often occurs in elderly patients and consists of 3–5%
of de novo AML. In particular, patients carrying MLL-PTD often have
a bad prognosis.3–6 MLL-PTD is generally believed to act as an
oncogenic driver by modulating expression of HOX genes.
However, mice carrying Mll-PTD alone do not develop spontaneous
leukemia,7 unless they are crossed with those harboring another
major leukemogenic driver (for example, Flt3-ITD),8 suggesting that
by itself Mll-PTD is not sufficient to transform hematopoietic cells. In
addition, the mutational landscape of MLL-PTD AML has not
been fully explored as this subtype constitutes only 9 of the 200
TCGA-AML samples.9,10 Identification of collaborating driver muta-
tions and, subsequently, the underlying molecular mechanisms
driving this AML subtype will enhance our understanding of this
devastating disease.
AML is viewed as a disease formed by sequential acquisition of
a number of mutations in long-lived, self-renewing hematopoietic
stem cells.10–12 Investigators have recently proposed that the
order of mutational acquisition has a substantial impact on clinical
response in myeloid neoplasms.13 In addition, the order of
acquiring mutations has profound implications for the design of
therapeutic strategies, where the greatest therapeutic benefits are
most likely gained by targeting the earliest initiating mutation. In
the context of MLL-PTD AML, deciphering the evolutionary
timeline of the acquisition of this gene is important. A strategy
based on DOT1L inhibition was recently proposed for treating
MLL-rearranged (MLL fusion/MLL-PTD) leukemia,14,15 and the
effectiveness of this strategy is reliant on an underlying
assumption that the alteration of MLL occurs as an early initiating,
clonal mutation. To examine the ordering of different mutations in
this rare but clinically important AML subtype and to identify
novel uncharacterized mutations, we performed whole-exome
and targeted sequencing on 85 MLL-PTD AML patients.
MATERIALS AND METHODS
Exome sequencing and target capture sequencing
AML samples were purified using Ficoll paque to enrich for mononuclear cells.
DNA samples were processed for whole-exome sequencing using SureSelect
XT or XT2 (for targeted sequencing) Target Enrichment System (Agilent
Technologies, Santa Clara, CA, USA) according to the manufacturer's protocol.
Sequence data were generated on Illumina HiSeq-2000 platform. Sequence
reads were aligned to human reference genome hg19 for both whole-exome
and targeted sequencing libraries using Novoalign V3.01.02 (http://www.
novocraft.com/) with parameter -F ILMFQ to reflect properly base sequencing
quality of our data sets. SAMtools (Version 0.1.19) was used to remove PCR
duplicates.
1Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore; 2Division of Hematology/Oncology, Cedars-Sinai Medical Center, UCLA School of
Medicine, Los Angeles, CA, USA; 3MLL Munich Leukemia Laboratory, Munich, Germany; 4Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University,
Kyoto, Japan; 5Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 6Laboratory of Sequence Analysis,
Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 7Division of Hematology, National Taiwan University Hospital, National Taiwan University,
Taiwan; 8Department of Pathology, Keio University School of Medicine, Tokyo, Japan and 9Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, USA.
Correspondence: Dr L-W Ding, Cancer Science Institute of Singapore, National University of Singapore, #13 North Core, MD6, Singapore 117599, Singapore.
E-mail: csidlw@nus.edu.sg
10These authors contributed equally to this work.
Received 2 December 2015; revised 21 May 2016; accepted 25 May 2016; accepted article preview online 8 June 2016; advance online publication, 8 July 2016
Leukemia (2017) 31, 1–10
www.nature.com/leu
Somatic SNV detection (with matched remission samples)
To identify somatic single-nucleotide variants (SNV) in patients with
matched remission samples, software MuTect (Version 1.1.4)16 was utilized
with default parameters. Annotation files corresponding to COSMIC
database (hg19-cosmic-v54-120711.vcf) and dbSNP database (dbsnp-132-
b37.leftAligned.vcf) were retrieved from MuTect website (http://www.
broadinstitute.org/cancer/cga/mutect-download) and utilized with MuTect
software for variant calls. Identified SNV passing the filtering criteria were
retained and used for downstream analysis.
Generation of false SNV list from panel of normal samples
Artifact detection mode of Mutect program was utilized to generate a list
of potential sequencing artifacts, mapping errors and common SNPs from
our in-house database of 240 normal samples (manually curated). Variants
that were positively identified in the normal samples by Mutect were
compiled to generate a putative list of false somatic SNVs. Somatic SNVs
detected from each normal-tumor pair were discarded if they were
similarly found in this list of false somatic SNVs.
See Supplementary data for a full description of Materials and Methods.
RESULTS
Mutational landscape of MLL-PTD AML
To generate a mutational spectrum for MLL-PTD AML, we initially
searched for cooperative driving events by performing exome
sequencing of genomic DNA of five MLL-PTD AML patients at
diagnosis, relapse and at complete remission (Supplementary
Table 1). Driver mutations (for example, FLT3, DNMT3A) were
clearly identified in all patients (Supplementary Table 2). The
analysis of the mutational spectrum indicates the dominance
of C4T transitions, which is in line with the finding of TCGA-
AML and is likely caused by spontaneous deamination of
methylcytosine17 related with aging (Supplementary Figure 1a).
The potential clonal architecture and clonal evolution were
subsequently inferred from the mutational data (Supplementary
Figures 1b and c). All of the patients shared a similar clonal
evolutionary pattern: despite achieving complete clinical hema-
tologic remission, the original founder clone of AML cells or the
pre-malignant clone survived chemotherapy, gained additional
mutations and reemerged at relapse (Supplementary Figure 1c).
We next extended our study to a larger group of MLL-PTD AML
patients (prevalence cohort). Mutated genes identified from the
discovery cohort and selected leukemia/cancer-related genes
(Supplementary Table 3, 530 genes) were chosen for targeted
sequencing on an additional 80 AML patients carrying the
MLL-PTD mutation (Supplementary Tables 4–6). A 259X mean
sequencing read depth was achieved for the prevalence cohort
(Supplementary Figure 2). A dominant C4T transition mutation
pattern was similarly found in the prevalence cohort, and
mutation signature 1b was identified as the dominant mutational
signature (Supplementary Figure 3, Alexandrov et al.18). At least
one well-known oncogenic driver mutation was identified in over
90% of the MLL-PTD patients (Figure 1, Supplementary Figure 4).
Recurrent hotspot mutations were noted in IDH1/2, U2AF1, NRAS
and FLT3, suggesting a potential gain-of-function effect of these
alterations. On the other hand, mutations of RUNX1, TET2, WT1,
STAG2 and ASXL1 were largely scattered throughout these genes
and tended to be inactivating, implying their potential tumor
suppressor roles in AML. Compared with the mutational landscape
of 200 TCGA-AML samples,9 several well-known leukemic drivers
(Figure 2, Supplementary Table 7) as well as a few novel genes
like MGA (9%) and members of the NOTCH family were enriched in
MLL-PTD-positive samples (Supplementary Figure 5). Remarkably,
no mutations of NPM1 were found in our patient cohort, although
it is one of the most frequently mutated AML genes identified by
TCGA (27%).9 The frequently mutated genes that we identified
Figure 1. Mutational landscape of 80 MLL-PTD patients. Types of alterations are color-coded (lower right side of the figure). FLT3-ITD: FLT3
internal tandem duplication. TKD: FLT3 tyrosine kinase domain mutations. For patients with diagnosis and relapse samples, only the diagnosis
mutations are shown (mutations of complete diagnosis-relapse trio patients are shown in Supplementary Figure 4). Only canonical hotspots
or fs/stop-gain mutations found in both diagnosis and remission were considered as ‘mutation also present at remission’.
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were classified into several categories: epigenetic regulators, RAS-
RTK pathway, transcriptional factors, cohesin complex and splicing
factors.
Mutations of epigenetic regulators
In line with earlier sequencing studies of other AML subtypes and
the TCGA-AML-sequencing project,9 DNMT3A was the most often
mutated epigenetic regulator (25%): the well-known hotspot
mutation R882H was found in 12 patients; S714C/F mutation was
detected in three patients. A dominant-negative role of these
missense mutations has been found and a tumor-suppressor
role of DNMT3A has been recently proposed.19–21 In addition,
frameshift and stop-gain DNMT3A mutations were found in six
patients. IDH1/IDH2 hotspot mutations were identified in 31% of
patients (R140Q (13 cases) or R172K (3 cases) in IDH2 and at R132
in IDH1 (4 cases)). The TET family was the third most prominently
mutated epigenetic regulator (TET1 (5%), TET2 (16.3%, six frame-
shift and three stop-gain)). In line with previous observations,3
mutually exclusive mutational patterns were noted between
IDH1/2 and TET1/2 (Supplementary Figure 6). Mutations of
epigenetic regulators also occurred in polycomb-associated
proteins (EZH2, ASXL family members, Supplementary Figure 7),
chromatin remodelers (ARID2, ARID1A), genes associated with
histone acetylation (CREBBP, EP300, KAT6A, KAT6B) and histone
methylation (MLL2, MLL3, MLL4).
Mutations in the RAS-FLT3 pathway are subclonal and tend to be
unstable
The proliferation-related pathway was extensively mutated,
with 54 of 80 MLL-PTD patients (67.5%) carrying at least one
mutation of the proliferative genes (Figure 3a). Specifically, FLT3
mutations were found in 46% of patient samples. These mutations
included: #1, internal tandem-duplications (ITD) in exon 14 (41 ITD
mutations in 27 patients, Supplementary Table 8); #2, well-known
hotspot mutations located in the kinase domain (D835/D839); #3,
recurrent in-frame (p.836_837) deletion in the kinase domain
(Figure 3b); #4, novel missense mutations in the juxta-membrane
domain. Notably, some FLT3-ITD patients had more than one
type of ITD insertion, which probably reflects the existence of
multiple subclones in their leukemia (Supplementary Table 8).
The presence of several ITD mutations in different subclones
signifies the prominent role of FLT3-ITD in accelerating clonal
expansion.
Importantly, mutations in FLT3 and other proliferation-
related genes were largely subclonal with median variant
allele-frequencies (VAFs) ranging from ~0.10–0.15 (Figure 3c).
Comparatively, mutations of epigenetic regulators (DNMT3A, IDH1,
IDH2, TET2), transcriptional factors (RUNX1, WT1), as well as a
splicing factor U2AF1 tended to have relatively high VAF
(~0.35–0.45, Figure 3c, Supplementary Figure 8), suggesting they
occurred earlier during leukemic evolution. Notably, clones
carrying FLT3 mutations were often found to be unstable and
frequently expanded or diminished during progression of disease
(6 of 13 patients who had matched relapse samples for analysis,
Figure 3d, Supplementary Figure 9). Interestingly, mutations
driving proliferation also appeared to be interchangeable during
the evolution of disease. In patient CH002, for example, the clone
carrying the Q61R NRAS mutation was readily observed at
diagnosis, but declined beyond the limits of detection in the
relapse sample (Figure 3e). In contrast, the clone carrying the FLT3
D839R mutation was identified in the relapse sample while it was
below the limits of detection (~400X) in the diagnosis sample
(Figure 3e and f). Similarly, in patient GR019, two FLT3-ITDs
(L610delins and N609delins) that were initially observed at
diagnosis, were not found at relapse. Coupled with this, a
relatively strong surge of a clone carrying another FLT3-ITD
(Y597delins) occurred in the relapse (Figure 3e). Furthermore,
multiple subclonal mutations carrying different proliferation
driving mutations could often be found in the patients’ AML
(Figure 3g). Collectively, these results support a model in which
diverse proliferative drivers were independently acquired in
different subclones derived from the founder clone.
Recurrent mutations of cohesin genes and splicing factors
Besides the well-established role in the control of separation of
the sister chromatids during cell division, cohesin proteins also
have important roles in the maintenance of genome stability, DNA
damage repair and regulation of gene transcription. Recurrent
mutations of genes in the cohesin complex have been reported in
a variety of cancers, including myelodysplastic syndromes,
myeloproliferative neoplasms and AML.22,23 Herein, we also found
highly prevalent mutations of the cohesin genes (STAG2 (16.3%),
SMC1A (6.3%), SMC3 (1%) and RAD21 (1%)) and CTCF (6%, a
transcription factor associated with the cohesin complex). In
totality, the cohesin pathway is more frequently mutated in
MLL-PTD patients (26%) than the AML samples from either TCGA
(13%, Po0.01) or a meta-analysis of 1000 AML (9.1%, Po0.0001).24
Remarkably, an extremely high proportion of the mutations had a
strong tendency to disrupt the coding sequence (eight stop-gain,
two frameshift and two splice-site mutations) in STAG2 (Figure 4a),
emphasizing its crucial tumor-suppressor role in this AML subtype
(16.3% in MLL-PTD vs 3% in TCGA-AML (Po0.01) and 3.2% in a
meta-analysis of 1102 AML24 (Po0.0001)). Interestingly, although
STAG2 mutations were found as early clonal mutations in our cohort
with mean VAFs of around 0.4, these mutations were lost at relapse
in two of the patients (Figure 4b-d), suggesting that maintenance of
the STAG2mutation may not be required for relapse. Consistent with
the notion of a functional overlap between mutations of the cohesin
genes, a mutually exclusive pattern was noted (Figure 4e and f).
Interestingly, a mutually exclusive pattern was also noted between
STAG2 and the splicing factor U2AF1. The underlying mechanism
behind this observation is currently unknown and requires
further studies. In addition, a mutually exclusive pattern was noted
between STAG2 and the other major AML drivers (except for IDH2
which tended to co-occur with STAG2) (Supplementary Figure 6).
The RNA processing pathway was also strikingly altered in MLL-
PTD patients. The most prominently mutated genes within this
category were the splicing factors. They included U2AF1 (12.5%,
Figure 2. Differing rates of mutation in AML: our MLL-PTD cohort
versus AMLs from TCGA. Comparison of the mutation rate of our 80
MLL-PTD AMLs and 200 AMLs from TCGA (includes nine MLL-PTD
samples). Mutated NPM1 gene was found only in TCGA AMLs.
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S34F/Y), SRSF2 (2.5%, hotspot position P95, Supplementary
Figure 10), SF3A1 (5%), ZRSR2 (2.5%), DHX15 (1%) and CWC22
(1%). We and others have hallmarked their importance by noting
their high frequency (460%) in myelodysplastic syndromes.25,26
Genes encoding RNA helicases (DDX10 (5%) and HELZ (3%)) were
also frequently altered in the prevalence cohort. This family of
proteins is involved in the regulation of RNA splicing, ribosome/
spliceosome assembly and initiation of translation.27 Mutations
were also identified in RNA processing and degradation proteins
DIS328 (9%) and SMG1 (2.5%).
MGA is a potential tumor suppressor
Another highly mutated novel gene was MGA, an incompletely
studied gene with a mutation frequency of 9% in MLL-PTD AML
(Figure 5a). It encodes a MAX-interacting protein and is believed
to act as a transcription factor that suppresses MYC binding to its
target. By in silico analysis, we found that MGA was expressed in
normal myeloid hematopoietic cells and AML (Supplementary
Figure 11). Further data mining of TCGA sequencing projects
revealed a high frequency of inactivating mutations of the MGA
gene in a variety of cancers (Figure 5b), suggesting a potential pan
Figure 3. Mutations in the RAS-FLT3 pathway are subclonal and tend to be unstable. (a) Mutational landscape of patients carrying PTPN11,
FLT3, NRAS and KRAS mutations. (b) Mutational diagram of FLT3 and NRAS in 80 MLL-PTD patients at diagnosis. In total, 41 FLT3-ITD mutations
were detected in 27 patients. (c) Variant allele frequency (VAF) plot of the frequently mutated genes. Mutations in epigenetic regulator genes
(blue) tend to have high VAF, whereas proliferation-related genes (red) tend to have low VAF, indicating that SNV mutations in proliferation-
related genes are generally subclonal and occur later than the genes involved in epigenetic regulation. FLT3 SNV (single nucleotide variant)
and FLT3-ITD are labeled separately. TCGA-AML result are shown as an insert. (d) FLT3 mutations are unstable during disease progression.
Schematic diagrams demonstrating the proportion and progression of the FLT3mutation carrying subclones inferred from their VAF in several
diagnosis (DX) and relapse (REL) pairs are shown. Sequencing read depth of each mutation position are displayed in Supplementary Figure 9.
(e) Mutations driving cell proliferation are replaceable during diagnosis and relapse. Upper pair, in patient CH002, mutant NRAS carrying
subclone was found at leukemic diagnosis, this subclone subsequently was eliminated by chemotherapy. However, the founding clone
survived during the chemotherapy, gained a FLT3 D839G mutation, and this alternative FLT3 carrying subclone (FLT3 D839G) expanded and
became the dominant clone at relapse. Lower pair, in patient GR019, leukemia at diagnosis harbored two different FLT3-ITD carrying
subclones, both were eliminated by chemotherapy. The founding clone survived the chemotherapy, and an alternative subclone derived from
the founding clone harbored a different FLT3-ITD mutation, which subsequently appeared at relapse. (f) Diagram depicting VAF and
sequencing read depth of NRAS and FLT3 mutations in patient CH002. Venn diagram indicates mutations that are either shared or distinct
between the DX and REL samples. (g) Two case examples indicating the presence of multiple subclones carrying different proliferative driver
mutations in patients’ AML cells.
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Figure 4. Members of the cohesin pathway are highly mutated in MLL-PTD AML. (a) Mutational diagram of the cohesin pathway genes in MLL-
PTD patients. (b) Representative Sanger sequencing tracing showing the STAG2 (X-chromosome gene) mutation in patients GR011, CH044 and
CH005. A complete C4T alteration was noted in patients GR011 and CH044 (both males), whereas heterozygous double peaks were noted in
patient CH005 (female). (c) Clones carrying STAG2 mutation were present as dominant clone at diagnosis, but either disappeared or shrank
drastically at relapse. GR011 at relapse had 7 of 146 STAG2 mutant reads detected by NGS sequencing (below the detection threshold of
Sanger sequencing, see Figure 6a and Supplementary Figure 13 where the number of mutant reads of STAG2 in patients GR011 and CH060 are
indicated). (d) Average VAF of STAG2 mutations in diagnosis samples corrected for gender of patients (X-chromosome gene). (e) Mutational
heatmap of cohesin pathway genes in TCGA-AML. Two patients had both MLL-PTD and cohesin mutations (highlighted with a yellow triangle).
One of the TCGA patients harbored a mutation of STAG2 in the same splicing site found in this study (highlighted with blue circle). (f) Mutual
exclusivity of mutations of genes in the cohesin pathway within our MLL-PTD AML cohort. (g) STAG2mutations are mutually exclusive with the
splicing factor U2AF1 mutations as noted in our MLL-PTD AML cohort. Upper panel, mutational diagram of splicing factor U2AF1. Lower panel,
mutually exclusive pattern between the samples carrying either STAG2 or U2AF1 mutations.
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cancer tumor suppressor role of this gene. To interrogate
functionally its role in leukemogenesis, lentiviral constructs
containing either shRNA or CRISPR-sgRNA targeted to different
regions of the MGA gene were generated (Supplementary Table 9).
MLL-PTD containing AML cell line EOL-129 was infected with the
shRNA/sgRNA viral particles. Stable cell lines were selected with
puromycin, and the silencing ability of the shRNAs towards MGA
was assessed by western blot and real-time PCR (Figure 5c and d,
Supplementary Table 10). Methylcellulose colony-formation assay
was subsequently employed to evaluate the effect of silencing
MGA. An increase of colony number (~30%) was observed in MGA
silenced cell lines (Figure 5c). Similarly, silencing of MGA by either
siRNA or CRISPR-sgRNA modestly increased the colony formation
(Figure 5e-g). Congruently, silencing of MGA by CRISPR-sgRNA
consistently enhanced the in vivo xenograft cell growth in NSG mice
(Figure 5h and i, Supplementary Figure 12). In addition, western blot
analyses revealed the elevation of p-RB and Cyclin E1 in the MGA
silenced cells (Figure 5d, Supplementary Figure 12), indicative of a
proliferative advantage conferred by the silencing of MGA.
As mentioned above, MGA may be a potential regulator of the
MYC pathway. We, therefore, examined whether silencing of MGA
alters MYC transcriptional activity. Luciferase reporter assay was
carried out in 293FT cells stabilized with either scramble or shRNA-
targeting MGA. A fourfold increase in luciferase activity was
observed in MGA silenced cells when compared with non-
targeting shRNA controls (Figure 5j). Furthermore, Kaplan–Meier
survival analysis of the TCGA-AML patients suggests that MGA
mRNA expression level is correlated with overall patient survival.
AML patients with lower levels of MGA in their leukemic samples
had a worse outcome compared with those whose leukemic cells
expressed higher levels of MGA (Figure 5k). Collectively, our results
suggest that MGA may function as a potential tumor-suppressor
in AML.
Initiating mutations often persist at remission
Strikingly, we observed that some early clonal mutations in
DNMT3A, TET2, IDH1/2, U2AF1 (herein termed remission-persisting
mutations) were retained with high VAF in a large proportion of
patients’ remission samples (29%, 8 of 28 patients); in contrast,
neither the MLL-PTD (determined by real-time RT-PCR (sensitive
range from 1:100-1:10 000, see Weisser et al.30) and by relative
copy number (RCN) analysis) as well as those associated with a
relatively later subclonal mutations (for example, FLT3/NRAS,
Figure 6a and Supplementary Figure 13) were detected. The fact
that DNMT3A/TET2/IDH1/2/U2AF1 mutations were detected at
both diagnosis and complete clinical morphological remission
(determined by normal morphology/cytogenetics, % blasts and
further supported by the disappearance of other mutations found
at diagnosis) suggests that these mutations are most likely present
prior to malignant transformation.10,12,31 Notably, recent studies
from several research groups have revealed a high prevalence of
hematologic cancer-related gene (DNMT3A, TET2, ASXL1) muta-
tions in normal individuals as they aged31–35 and these mutations
are associated with an increased risk for the development of
hematologic cancer. Collectively, our observations suggest that
chemotherapy eliminated the malignant leukemic cells and
reverted these patients back to a pre-leukemic (clonal hematopoi-
esis) instead of a completely normal state (polyclonal hematopoi-
esis). These remission-persisting mutations carrying clones may
act as a reservoir for subsequent relapse.36
Ordering of mutations in MLL-PTD AML
To identify the mutation order of the MLL-PTD aberration in
relation to other mutations, we performed copy number analysis
of MLL-PTD. The tandem duplication of MLL gene leads to a copy
number gain of the affected exons. By analyzing the sequencing
read depth of each exon (normalized with the local and global
capturing efficiency, Supplementary Figures 14–16), the RCN of
each exon of the MLL gene can be calculated and the proportion
of mutation carrying cells inferred (see Supplementary Results for
full discussion). Guided by this notion, we calculated the RCN
value of each exon of the MLL gene for 28 paired MLL-PTD
samples with matched remission control. For most of the samples,
we found a mean RCN of ~ 1.5 for exons 3–9 and a RCN value of
~ 1 in the other exons (Figure 6b and c). At the same time, a
control analysis was performed with TCGA-AML patient’s exome-
sequencing data (excluding the nine MLL-PTD patients) and 200
ALL patients targeted sequencing data (Supplementary Figure 15),
Figure 5. MGA is a potential tumor-suppressor mutated in MLL-PTD AML. (a) Diagram showing the mutational type and position within the
MGA gene identified in MLL-PTD samples. Missense mutations R796K and V1193I of MGA occurred in the same sample. (b) High proportion of
inactivating mutations were observed in MGA in a variety of cancers. Adeno, adenocarcinoma; ACYC, adenoid cystic carcinoma. (c) Enhanced
colony formation in EOL-1 cells after silencing MGA with either shMGA-1 or shMGA-2. Left panel, real-time PCR result shows the silencing
effect of MGA by two shRNAs; right panel, colony formation result of EOL-1 cell after silencing MGA with two shRNA. Mean± s.d., n= 3,
*Po0.05; ***Po0.001. Lower panel, representative photographs of EOL-1 colonies formed in methylcellulose of non-target shRNA (left
photos) and shRNA silenced MGA (middle and right photos). (d) Silencing of MGA in EOL-1 cells increased protein levels of Cyclin E1 and
phos-RB (S807, phosphorylation inhibits RB target binding and allow cell cycle progression). A representative western blot of four
independent experiments is shown. (e) Enhanced colony formation in EOL-1 and KOPM88 cells after silencing MGA with siRNA pool
(SMARTpool: ON-TARGETplus MGA siRNA, Dharmacon). SiRNA was delivered using Nucleofector™ electroporation device (Lonza). Transfection
efficiency was480% in both cell lines as determined by the co-transfected GFP. Left panel, real-time PCR result showing the silencing effect of
MGA by siRNA pool in EOL-1 and KOPM88 cells; right panel, colony formation result of EOL-1 and KOPM88 cells after silencing MGA with
siRNA pool. Mean± s.d., n= 3. *Po0.05; ***Po0.001. (f) Sanger sequencing tracings depicting the frameshift insertion of a T nucleotide
induced by CRISPR sgMGA-3 in EOL-1 cell line (see Supplementary Figures12c and d for detailed sequencing tracing and BLAST result).
(g) Enhanced colony formation in EOL-1 after silencing MGA with CRISPR-sgRNA. Left panel, real-time PCR result indicating the silencing effect
of MGA by a single CRISPR guide RNA (sgMGA-3) or a mixture of three sgRNAs targeting MGA (sgMGA-1,2,3); right panel, the colony-formation
result of EOL-1 cell after silencing MGA with sgMGA-3 or a mixture of three sgRNAs designed to target MGA (sgMGA-1,2,3). Real-time PCR and
colony-formation assay were performed 15 days after the lentiviral infection (3 days for virus infection, 7 days for puromycin selection and
5 days with normal medium). Mean± s.d., n= 3. *Po0.05; ***Po0.001. (h and i) Enhanced tumor mass of MGA knockout EOL-1 cell in an
in vivo xenograft model. Control EOL-1 cells or EOL-1 cells silenced with MGA CRISPR sgRNAs were injected into both flanks of NSG mice, and
tumor masses were harvested 21 days after injection. (h) Photo of tumor masses dissected from the NSG mice, which were injected with EOL-1
cells after silencing MGA expression by CRISPR sgMGA-3 (upper panel) or control EOL-1 cells (lower panel); (i) Barplots indicating the weight of
the tumor mass. Mean± s.d., n= 10, **Po0.01. (j) Increased MYC activity in 293FT cells after stable silencing of MGA by shRNA. Luciferase
activities were measured 48 h after transfection of cells with MYC activity reporter pMyc4ElbLuc (Addgene, #53246) and normalized to the
corresponding co-transfected Renilla luciferase activity. Mean± s.d., n= 3, **Po0.01. (k) Kaplan–Meier plot of overall survival: comparison of
cases with highest versus lowest expression of MGA in AML patients. P-values were calculated by log-rank test. MGA expression data and
patient survival data were retrieved from TCGA-AML patients RNA seq (left panel), or microarray (70 AML patients) (right panel). The MGA
expression ‘high’ and ‘low’ groups were defined by 15% higher than the median or 15% lower than the median, respectively.
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which revealed a RCN value of ~ 1 in all MLL exons (Figure 6c).
Taken together, the observed RCN of duplicated MLL-PTD exons of
~ 1.5 (Figure 6c) suggests the presence of MLL-PTD as a clonal
mutation in most of the MLL-PTD patients.
MLL-PTD is a highly specific AML driver
Our observation of MLL-PTD as an early clonal driver mutation in
AML raises an intriguing question of whether MLL-PTD may serve
similar roles in other cancer types. MLL-PTD manifests as a tandem
duplication of exons 3–9 of MLL gene. The length of exons 3–9 of
MLL is ~ 12.5 kb, suggesting that SNP-arrays can identify the
MLL-PTD alteration. Indeed, canonical MLL-PTD involving exons
3–9 was identified in the EOL-1 (known to carry MLL-PTD
mutation29), as well as the Kasumi-6 AML cell line (Supplementary
Figures 15c and d). Furthermore, AML samples known to have
MLL-PTD can also be detected by analysis of the TCGA SNP-array
database (Supplementary Figure 15e), suggesting that SNP-array
is a valid platform for the detection of MLL-PTD. Upon
further examination of 1000 different cancer cell lines in CCLE,
10 000 different cancer samples in TCGA SNP-array database
(Broad-Firehose-standard-data-run2015_04_02) and a panel of
2792 samples of different cancer types in the Tumorscape SNP-
array database, we conclude that the gain of exon 3–9 in MLL, as a
clonal mutation, is likely only present in AML, suggesting that
MLL-PTD is a rare and highly specific AML driver.
DISCUSSION
In this study, we found that multiple mutations co-occur with
MLL-PTD and mutations are usually acquired in a sequential
manner. A potential ordering for acquisition of mutations was
proposed (IDH2/DNMT3A/U2AF1/TET2→MLL-PTD→RAS-RTK) based
on the following reasons: #1, real-time-PCR (Figure 6a) showed
that MLL-PTD was absent in remission while mutations of IDH2,
DNMT3A, TET2 and U2AF1 were still retained with a high VAF. This
suggests that MLL-PTD was acquired after mutations of IDH2,
DNMT3A, TET2 and U2AF1; #2, MLL-PTD is highly stable during
disease progression as compared with mutations of the RAS-RTK.
In a previous study characterizing 46 AML patients carry MLL-PTD
mutation at diagnosis, MLL-PTD persisted in 43 of these
individuals at relapse.30 On the other hand, as shown in
Figure 3, RAS-RTK mutations frequently exist as subclonal
mutations and tend to be unstable during disease progression.
These observations support a notion that MLL-PTD was acquired
prior to RAS-RTK. Taken together, the above reasoning suggests
MLL-PTD is acquired after those remission-persisting, initiating
mutations (IDH2, DNMT3A, TET2 and U2AF1), but prior to lesions of
the proliferation-related driver (Figure 6d), highlighting its critical
role in the development of full-blown AML. Indeed, our
observations and inference of clonal early/late mutations are
consistent with recent reports of healthy elderly individuals
carrying functionally inactivating DNMT3A/TET2 mutations,31–34
as well as previous studies from the DNMT3A and TET2 knockout
mouse model.37–39 These studies point to a model where a
pre-malignant founder clone is formed following acquisition of an
initiating mutation and where the subsequent gain of cooperating
mutations in these pre-leukemic cells leads to the onset of
leukemogenesis. In this paradigm, MLL-PTD can thus be viewed as
one of the early cooperating mutations. Interestingly, one of the
most frequently mutated AML genes, NPM1, is mutually exclusive
with MLL-PTD. Mutations of NPM1 are usually present as early
clonal mutations in AML blasts, but are absent in normal
appearing elderly individuals who can carry mutations of DNMT3A
and TET2.32–34,40 This observation implies that, similar to MLL-PTD,
NPM1 mutations can also be considered as one of the early
cooperating mutations. In this regards, MLL-PTD and NPM1may be
involved in similar pathways to trigger AML as inferred from their
mutually exclusive pattern.
Based on our observations and previous studies of normal
elderly individuals,32–34,40 a potential molecular boundary can be
defined to distinguish the leukemic and pre-leukemic stage: the
initiating mutations (DNMT3A and so on) were detected in both
pre- and bonafide leukemia as well as in 10% of normal individuals
over the age of 65,32–34,40 whereas the early mutations of RUNX1,
WT1, NPM1, STAG2 and so on were usually only found in frank
leukemic blast cells (and in myelodysplastic syndromes/myelo-
proliferative neoplasms). Therefore, these early mutations (RUNX1,
WT1, NPM1 and so on) rather than the initiating mutations, will
likely be the most informative markers for the measurement of
minimal-residual disease.41
In the design of targeted therapeutic strategies for cancer
patients, high priority should be accorded to the ‘trunk’ mutations
that are present in the majority of the cancer cells. The molecular
timeline model established here suggests that, despite the
observed high prevalence of RAS-RTK mutations in MLL-PTD
AML, most of these mutations are present in only a fraction of the
cancer cells. Thus, targeting these late subclonal events may have
only limited therapeutic value.
During submission of our manuscript, another article on MLL-
rearranged AML appeared;42 this article identified LOC100289656
as a specific MLL fusion AML marker and focused on analysis of
the transcriptome and mutation of MLL fusion AML patients.
Conversely, our study focuses on MLL-PTD instead of MLL fusion,
which distinguishes our study from their report.
In summary, our analysis of the mutational landscape of 85 MLL-
PTD AML patients revealed the sequential pattern of mutational
acquisition and a number of co-occurring mutations. This study
provides a detailed mutational profile and approximate timeline
for a unique AML subtype, which may guide the development of
more effective therapeutic approaches and further pave the way
for AML personalized therapeutic strategies.
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Figure 6. MLL-PTD is a clonal mutation that occurs before mutations of the RAS-RTK pathway, but later than the IDH2/DNMT3A/U2AF1/TET2
mutations. (a) AML mutations of either IDH2, TET2, DNMT3A, U2AF1 (colored in red) persist in the remission samples of eight patients with
matched remission control (plot of two patients are shown in Supplementary Figure 13). Sequencing read depth of each mutation at different
time point is indicated (mutant reads/total read of the indicated position). MLL-PTD level at each time point was determined by quantitative
RT-PCR to calculate the MLL-PTD ratio (normalized copy number of MLL-PTD to ABL1 ratio ((MLL-PTD/ABL) × 100) according to the method
described in Weisser et al.30). (b) Diagram illustrating the relative copy number of each exon of the MLL gene. Inner picture depicts the
expected relative copy number between DX and CR samples for exons affected by MLL-PTD (exons 3–9), and those unaffected by the
aberration (other exons). Gain of exons 3–9 of the MLL gene could be observed in 28 MLL-PTD patients with matched remission control. (c)
Diagram illustrating the relative copy number of exons 3–9 or exons 1–2, 10–37 of the MLL gene in 28 pair MLL-PTD patients, 200 pediatric ALL
patients (Supplementary Figure 15b) and 120 TCGA-AML patients (the 9 MLL-PTD samples were excluded). (d) Mutational timeline model for
the sequence of acquisition of IDH2/DNMT3A/U2AF1/TET2, MLL-PTD and the FLT3/NRAS/KRAS/PTPN11 mutations in MLL-PTD AML patients.
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